These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 29738880)
1. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration? Yan X; Uronen RL; Huttunen HJ Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880 [TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein and tau: teammates in neurodegeneration? Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339 [TBL] [Abstract][Full Text] [Related]
3. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Lee VM; Giasson BI; Trojanowski JQ Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877 [TBL] [Abstract][Full Text] [Related]
4. Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases. Hart de Ruyter FJ; Evers MJAP; Morrema THJ; Dijkstra AA; den Haan J; Twisk JWR; de Boer JF; Scheltens P; Bouwman FH; Verbraak FD; Rozemuller AJ; Hoozemans JJM Acta Neuropathol; 2024 Aug; 148(1):24. PubMed ID: 39160362 [TBL] [Abstract][Full Text] [Related]
5. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Goedert M; Masuda-Suzukake M; Falcon B Brain; 2017 Feb; 140(2):266-278. PubMed ID: 27658420 [TBL] [Abstract][Full Text] [Related]
6. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472 [TBL] [Abstract][Full Text] [Related]
7. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Goedert M Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313 [TBL] [Abstract][Full Text] [Related]
8. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Guo JL; Covell DJ; Daniels JP; Iba M; Stieber A; Zhang B; Riddle DM; Kwong LK; Xu Y; Trojanowski JQ; Lee VM Cell; 2013 Jul; 154(1):103-17. PubMed ID: 23827677 [TBL] [Abstract][Full Text] [Related]
9. Tau and Alpha Synuclein Synergistic Effect in Neurodegenerative Diseases: When the Periphery Is the Core. Vacchi E; Kaelin-Lang A; Melli G Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708732 [TBL] [Abstract][Full Text] [Related]
10. A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration. Ciaccioli G; Martins A; Rodrigues C; Vieira H; Calado P PLoS One; 2013; 8(2):e55848. PubMed ID: 23393603 [TBL] [Abstract][Full Text] [Related]
11. Interface between tauopathies and synucleinopathies: a tale of two proteins. Galpern WR; Lang AE Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609 [TBL] [Abstract][Full Text] [Related]
12. Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration. Yeboah F; Kim TE; Bill A; Dettmer U Neurobiol Dis; 2019 Dec; 132():104543. PubMed ID: 31351173 [TBL] [Abstract][Full Text] [Related]
13. Structural basis of the interplay between α-synuclein and Tau in regulating pathological amyloid aggregation. Lu J; Zhang S; Ma X; Jia C; Liu Z; Huang C; Liu C; Li D J Biol Chem; 2020 May; 295(21):7470-7480. PubMed ID: 32291284 [TBL] [Abstract][Full Text] [Related]
14. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Sengupta U; Kayed R Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272 [TBL] [Abstract][Full Text] [Related]
15. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802 [TBL] [Abstract][Full Text] [Related]
16. Interactions of pathological proteins in neurodegenerative diseases. Spires-Jones TL; Attems J; Thal DR Acta Neuropathol; 2017 Aug; 134(2):187-205. PubMed ID: 28401333 [TBL] [Abstract][Full Text] [Related]
17. Protein Partners of α-Synuclein in Health and Disease. Lassen LB; Reimer L; Ferreira N; Betzer C; Jensen PH Brain Pathol; 2016 May; 26(3):389-97. PubMed ID: 26940507 [TBL] [Abstract][Full Text] [Related]
18. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein. Martinez-Valbuena I; Valenti-Azcarate R; Amat-Villegas I; Marcilla I; Marti-Andres G; Caballero MC; Riverol M; Tuñon MT; Fraser PE; Luquin MR Acta Neuropathol Commun; 2021 Apr; 9(1):64. PubMed ID: 33832546 [TBL] [Abstract][Full Text] [Related]
19. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812 [TBL] [Abstract][Full Text] [Related]
20. Patterns of Tau and α-Synuclein Pathology in the Visual System. Rahimi J; Milenkovic I; Kovacs GG J Parkinsons Dis; 2015; 5(2):333-40. PubMed ID: 25737267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]